Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: September 2025
Date Filed: September 17, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of corporate governance changes rather than a financial performance update.
Material Changes
The primary material change disclosed in this filing is the submission of four "Change of Director's Interest Notice" exhibits (Exhibit 99.1). No other operational or financial changes are detailed in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is incorporated by reference into Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the specific details of the four Director's Interest changes referenced in Exhibit 99.1.
- Review the referenced Registration Statements (Form S-8 and Form F-3) for broader context on capital structure and securities offerings.
- Confirm the company's status as a development stage enterprise and its current cash runway, as no financial data is present in this specific filing.